{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:38:09Z","timestamp":1793363889464,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["9980"],"award-info":[{"award-number":["9980"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["2010\/15"],"award-info":[{"award-number":["2010\/15"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["2016\/18"],"award-info":[{"award-number":["2016\/18"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jpba.2020.113451","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T11:55:28Z","timestamp":1593431728000},"page":"113451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS\/MS"],"prefix":"10.1016","volume":"188","author":[{"given":"Samantha","family":"Franzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Morbioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Turtoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Solazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariamena","family":"Arbitrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Di Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2020.113451_bib0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jpba.2020.113451_bib0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/2159-8290.CD-15-0893","article-title":"MicroRNA deregulation in cancer cells and the tumor microenvironment","volume":"6","author":"Rupaimoole","year":"2016","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.jpba.2020.113451_bib0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/17474086.2018.1517041","article-title":"The potential role of miRNAs in multiple myeloma therapy","volume":"11","author":"Caracciolo","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.jpba.2020.113451_bib0020","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1517\/14712598.2013.807338","article-title":"Emerging pathways as individualized therapeutic target of multiple myeloma","volume":"13","author":"Misso","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jpba.2020.113451_bib0025","doi-asserted-by":"crossref","first-page":"17949","DOI":"10.1038\/s41598-017-18186-0","article-title":"Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment","volume":"7","author":"Zarone","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jpba.2020.113451_bib0030","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/leu.2017.336","article-title":"MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells","volume":"32","author":"Botta","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jpba.2020.113451_bib0035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41375-018-0238-2","article-title":"miR-22 suppresses DNA ligase III addiction in multiple myeloma","volume":"33","author":"Caracciolo","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jpba.2020.113451_bib0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/23808993.2016.1142356","article-title":"Experimental treatment of multiple myeloma in the era of precision medicine","volume":"1","author":"Di Martino","year":"2016","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"issue":"10","key":"10.1016\/j.jpba.2020.113451_bib0045","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2018-03-836601","article-title":"Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92","volume":"32","author":"Morelli","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2020.113451_bib0050","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13046-018-0767-6","article-title":"miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20\/c-Rel\/CTGF signalling","volume":"37","author":"Santolla","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2020.113451_bib0055","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/14728222.2016.1164693","article-title":"Mir-221\/222 are promising targets for innovative anticancer therapy","volume":"20","author":"Di Martino","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jpba.2020.113451_bib0060","doi-asserted-by":"crossref","first-page":"242","DOI":"10.18632\/oncotarget.820","article-title":"In vitro and in vivo anti-tumor activity of miR-221\/222 inhibitors in multiple myeloma","volume":"4","author":"Di Martino","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpba.2020.113451_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089659","article-title":"In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells","volume":"9","author":"Di Martino","year":"2014","journal-title":"PLoS One"},{"issue":"32","key":"10.1016\/j.jpba.2020.113451_bib0070","doi-asserted-by":"crossref","first-page":"23716","DOI":"10.1074\/jbc.M701805200","article-title":"miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1","volume":"282","author":"Galardi","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jpba.2020.113451_bib0075","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1073\/pnas.0907904107","article-title":"miR-221 overexpression contributes to liver tumorigenesis","volume":"107","author":"Pineau","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpba.2020.113451_bib0080","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1038\/mtna.2016.36","article-title":"Pharmacokinetics and pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in mice and non-human Primates","volume":"5","author":"Gallo Cantafio","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jpba.2020.113451_bib0085","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1158\/1078-0432.CCR-15-0489","article-title":"A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells","volume":"22","author":"Gulla","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2020.113451_bib0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/cancers12010027","article-title":"Allometric scaling approached for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221","volume":"12","author":"Di Martino","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jpba.2020.113451_bib0095","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jpba.2017.12.027","article-title":"Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC-MS\/MS","volume":"150","author":"Franzoni","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113451_bib0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.omtn.2020.01.036","article-title":"Dose-finding study and pharmacokinetics profile of the novel 13-Mer antisense miR-221 inhibitor in sprague-dawley rats","volume":"20","author":"Di Martino","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jpba.2020.113451_bib0105","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"US FDA","year":"2018"},{"key":"10.1016\/j.jpba.2020.113451_bib0110","series-title":"Guideline on Bioanalytical Method Validation","author":"EMEA","year":"2011"},{"key":"10.1016\/j.jpba.2020.113451_bib0115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jchromb.2018.05.025","article-title":"Review on sample preparation methods for oligonucleotides analysis by liquid chromatography","volume":"1090","author":"Nuckowski","year":"2018","journal-title":"J. Chromatogr. B"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708520313376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708520313376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:48:23Z","timestamp":1778539703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708520313376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":23,"alternative-id":["S0731708520313376"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113451","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113451"}}